Salinomycin in cancer: A new mission for an old agent

Molecular Medicine Reports

Volumn 3, Issue 4, 2010, Pages 555-559

  Naujokat, Cord ^a   Fuchs, Dominik ^b   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer agent; Apoptosis; Apoptosis resistance; Cancer cells; Cancer stem cells; Salinomycin

Indexed keywords

BORTEZOMIB; CAMPTOTHECIN; DACTINOMYCIN; DOXORUBICIN; PACLITAXEL; SALINOMYCIN; STAUROSPORINE;

ADULT; ANIMAL EXPERIMENT; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; REVIEW;

MUS; STREPTOMYCES ALBUS; SUIDAE;

EID: 77956689711     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000296     Document Type: Review

References (51)

1. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O and Hirsoe C: Salinomycin, a new polyether antibiotic. J Antibiot 27: 814-821, 1974.
2. Kinashi H, Otake N, Yonehara H, Saito S and Saito Y: The structure of salinomycin, a new member of the polyether antibiotics. Tetrahedron Lett 14: 4955-4958, 1973.
3. Mitani M, Yamanishi T and Miyazaki Y: Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun 27: 1231-1236, 1975.
4. Mitani M, Yamanishi T, Miyazaki Y and Otake N: Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother 9: 655-660, 1976.
5. Pressman BC and Lattanzio FA: Cardiovascular effects of ionophores. In: Frontiers of Biological Energetics Vol 2. Dutton PL, Leigh JS and Scarpa A (eds). Academic Press, New York, pp245-1252, 1978.
6. Mahmoudi N, De Julian-Ortiz JV, Ciceron L, et al: Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother 57: 489-497, 2006.
7. Danforth HD, Ruff MD, Reid WM and Miller RL: Anticoccidial activity of salinomycin in battery raised broiler chickens. Poult Sci 56: 926-932, 1977.
8. Daugschies A, Gässlein U and Rommel M: Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials. Vet Parasitol 76: 163-171, 1998.
9. Callaway TR, Edrington TS, Rychlik JL, et al: Ionophores: their use as ruminant growth promotants and impact on food safety. Curr Issues Intest Microbiol 4: 43-51, 2003.
10. Lindemann MD, Kornegey ET, Stahly TS, Cromwell GL, Easter RA, Kerr BJ and Lucas DM: The efficacy of salinomycin as a growth promotant for swine from 9-97 kg. J Anim Sci 61: 782-788, 1985.
11. Butaye P, Devriese LA and Haesebrouck F: Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin Microbiol Rev 16: 175-188, 2003.
12. Fahim M, Del Valle G and Pressman BC: Comparison of the effects of the ionophore salinomycin and adrenaline on the haemodynamics and work efficiency of the dog heart. Cardiovasc Res 20: 145-152, 1986.
13. Plumlee KH, Johnson B and Galey FD: Acute salinomycin toxicosis in pigs. J Vet Diagn Invest 7: 419-420, 1995.
14. Van der Linde-Sipman JS, van der Ingh TS, van Nes JJ, Verhagen H, Kersten JG, Beynen AC and Plekkringa R: Salinomycin-induced polyneuropathy in cats: morphologic and epidemiologic data. Vet Pathol 36: 152-156, 1999.
15. Aleman M, Magdesian KG, Peterson TS and Galey FD: Salinomycin toxicosis in horses. J Am Vet Med Assoc 230: 1822-1826, 2007.
16. Story P and Doube A: A case of human poisoning by salinomycin, an agricultural antibiotic. N Z Med J 117: 799, 2004.
17. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
18. Ward RJ and Dirks PB: Cancer stem cells: at the headwater of tumor development. Annu Rev Pathol 2: 175-189, 2007.
19. Frank NY, Schatton T and Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50, 2010.
20. Ailles LE and Weissman IL: Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466, 2007.
21. Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
22. Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angionesis. J Clin Oncol 26: 2839-2845, 2008.
23. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659, 2009
24. Elenbaas B, Spirio L, Koerner F, et al: Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15: 50-65, 2001.
25. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654, 2008.
26. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
27. Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226, 2007.
28. Shipitsin M, Campbell LL, Argani P, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273, 2007.
29. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003.
30. Fuchs D, Daniel V, Sadeghi M, Opelz G and Naujokat C: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 394: 1098-1104, 2010.
31. Wulf GG, Wang RY, Kuehnle I, et al: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173, 2001.
32. Eckford PD and Sharom FJ: ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109: 2989-3011, 2009
33. Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9, 2009
34. Fuchs D, Heinold A, Opelz G, Daniel V and Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 390: 743-749, 2009.
35. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
36. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
37. Nencioni A, Wille L, Dal Bello G, et al: Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2 overexpressing cells. Clin Cancer Res 11: 4259-4265, 2005.
38. Fuchs D, Berges C, Opelz G, Daniel V and Naujokat C: Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 103: 270-283, 2008.
39. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C and Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype and resistance to cyclosporins. J Biol Chem 272: 5974-5982, 1997.
40. Leoni LM, Hamel E, Genini D, Shih H, Carrera CJ, Cottam HB and Carson DA: Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst 92: 217-224, 2000.
41. Kuznetsov G, Xu Q, Rudolph-Owen L, et al: Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 8: 1250-1260, 2009
42. Lage H: An overview of cancer multidrug resistance: a still unresolved problem. Cell Mol Life Sci 65: 3145-3167, 2008.
43. Wolter KG, Verhaegen M, Fernandez Y, et al: Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14: 1605-1616, 2007.
44. Smith L, Lind MJ, Drew PJ and Cawkwell L: The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer drugs. Eur J Cancer 43: 2330-2338, 2007.
45. Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4: 1693-1698, 2005.
46. Wilson TR, Johnston PG and Longley DB: Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9: 307-319, 2009
47. + efflux in the activation of apoptosis. J Biol Chem 272: 32436-32442, 1997
48. + channels in apoptosis. J Membrane Biol 209: 3-20, 2006.
49. + channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 448: 274-286, 2004.
50. + channel expression in human breast cancer cells: involvement in cell cycle regulation and apoptosis. J Membrane Biol 221: 1-6, 2008.
51. Villalonga N, Ferreres JC, Argiles JM, Condom E and Felipe A: Potassium channels are a new target field in anticancer drug design. Recent Pat Anticancer Drug Discov 2: 121-123, 2007